Reducing Cancer Related Fatigue: the Untire App

  • Research type

    Research Study

  • Full title

    Reducing Cancer Related Fatigue: Untire App as an Evidence-Based mHealth Solution

  • IRAS ID

    239359

  • Contact name

    Anne Looijmans

  • Contact email

    a.looijmans@umcg.nl

  • Sponsor organisation

    University Medical Center Groningen

  • Clinicaltrials.gov Identifier

    NTR6828, Dutch Trial Register (www.trialregister.nl)

  • Duration of Study in the UK

    1 years, 0 months, 0 days

  • Research summary

    Is the Untire App effective in reducing Cancer Related Fatigue in (former) cancer patients?
    BACKGROUND
    Over 50% of the 14 million European cancer patients experience cancer related fatigue. Severe fatigue lasts for up to 10 years in at least 30% of cancer survivors, affecting their daily activities and quality of life. This project aims to assess whether the Untire app can reduce Cancer Related Fatigue (CRF) and improve Quality of Life (QoL) in (former) cancer patients.
    INTERVENTION
    Participants in the intervention group receive 6 months of free access to the Untire app. The Untire app uses beneficial therapeutic elements from clinical practice and is developed based on academic psycho-oncology research. The app offers participants a daily program with educational themes, exercises, stress-reduction exercises and tips, aiming to adjust participants’ thoughts and behaviors related to fatigue. Participants in the control group have no access to the app during the study. They receive 6 months of free access after completing their 12-weeks measure.
    PARTICIPANTS
    The study targets (former) cancer patients (18 years and older) who experience CRF and have a smartphone. Individuals with a mental disorder, chronic fatigue syndrome/myalgic encephalomyelitis or fibromyalgia cannot participate. Participants are recruited online via Lymphoma coalitions and social media.
    DESIGN
    In this international trial, we compare CRF and QoL in participants after 12 weeks of app use (intervention group) versus CRF and QoL in participants not using the app (controls). The app is available in the English-speaking countries (US, UK, Canada, Australia and New-Zealand) from start of the trial (phase 1) and will be translated and launched during the trial in non-English speaking countries (Germany, Spain and The Netherlands; phase 2). In phase 1, participants are randomly appointed to the control or intervention group. In phase 2, the period in which the app is not available, is the control group; the period in which the app is available, is the intervention group.
    DATA
    Data on CRF and QoL are gathered using online questionnaires at baseline, and after 4, 8, 12 and 24 weeks.
    FUNDING
    The University Medical Center Groningen, the Netherlands conducts this study and is partner of Tired of Cancer BV., who received a Grant of the European Union.

  • REC name

    Wales REC 5

  • REC reference

    18/WA/0003

  • Date of REC Opinion

    22 Dec 2017

  • REC opinion

    Favourable Opinion